A CD13 inhibitor, ubenimex, synergistically enhances the effects of anticancer drugs in hepatocellular carcinoma

International Journal of Oncology

Volumn 49, Issue 1, 2016, Pages 89-98

  Yamashita, Masafumi ^a   Wada, Hiroshi ^a   Eguchi, Hidetoshi ^a   Ogawa, Hisataka ^a   Yamada, Daisaku ^a   Noda, Takehiro ^a   Asaoka, Tadafumi ^a   Kawamoto, Koichi ^a   Gotoh, Kunihito ^a   Umeshita, Koji ^b   Doki, Yuichiro ^a   Mori, Masaki ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Cancer stem cells; CD13 antigen; Hepatocellular carcinoma; Reactive oxygen species; Ubenimex

Indexed keywords

BESTATIN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; MICROSOMAL AMINOPEPTIDASE; REACTIVE OXYGEN METABOLITE; SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; LEUCINE; NICOTINAMIDE;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; DRUG EXPOSURE; DRUG MECHANISM; DRUG POTENTIATION; HEPATOCELLULAR CARCINOMA CELL LINE; HUH7 CELL LINE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PLC CELL LINE; PRIORITY JOURNAL; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CANCER STEM CELL; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LIVER NEOPLASMS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTIGENS, CD13; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL LINE, TUMOR; CISPLATIN; DRUG SYNERGISM; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUCINE; LIVER NEOPLASMS; NEOPLASTIC STEM CELLS; NIACINAMIDE; PHENYLUREA COMPOUNDS; REACTIVE OXYGEN SPECIES;

EID: 84978402689     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2016.3496     Document Type: Article

References (55)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
2. Forner A, Llovet JM and Bruix J: Hepatocellular carcinoma. Lancet 379: 1245-1255, 2012.
3. Tomimaru Y, Wada H, Eguchi H, Tomokuni A, Hama N, Kawamoto K, Marubashi S, Umeshita K, Doki Y, Mori M, et al: Clinical significance of surgical resection of metastatic lymph nodes from hepatocellular carcinoma. Surg Today 45: 1112-1120, 2015.
4. Kobayashi T, Ishiyama K and Ohdan H: Prevention of recurrence after curative treatment for hepatocellular carcinoma. Surg Today 43: 1347-1354, 2013.
5. Valent P, Bonnet D, De Maria R, Lapidot T, Copland M, Melo JV, Chomienne C, Ishikawa F, Schuringa JJ, Stassi G, et al: Cancer stem cell definitions and terminology: The devil is in the details. Nat Rev Cancer 12: 767-775, 2012.
6. Bonnet D and Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3: 730-737, 1997.
7. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988, 2003.
8. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, Van Belle PA, Xu X, Elder DE and Herlyn M: A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 65: 9328-9337, 2005.
9. O'Brien CA, Pollett A, Gallinger S and Dick JE: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445: 106-110, 2007.
10. Ma S, Lee TK, Zheng BJ, Chan KW and Guan XY: CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 27: 1749-1758, 2008.
11. Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P, Chu PW, Lam CT, Poon RT and Fan ST: Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 13: 153-166, 2008.
12. Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, Jia H, Ye Q, Qin LX, Wauthier E, et al: EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 136: 1012-1024, 2009.
13. Zhu Z, Hao X, Yan M, Yao M, Ge C, Gu J and Li J: Cancer stem/ progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int J Cancer 126: 2067-2078, 2010.
14. Stange T, Kettmann U and Holzhausen HJ: Immunoelectron microscopic single and double labelling of aminopeptidase N (CD 13) and dipeptidyl peptidase IV (CD 26). Acta Histochem 98: 323-331, 1996.
15. Dixon J, Kaklamanis L, Turley H, Hickson ID, Leek RD, Harris AL and Gatter KC: Expression of aminopeptidase-n (CD 13) in normal tissues and malignant neoplasms of epithelial and lymphoid origin. J Clin Pathol 47: 43-47, 1994.
16. Bhagwat SV, Lahdenranta J, Giordano R, Arap W, Pasqualini R and Shapiro LH: CD13/APN is activated by angiogenic signals and is essential for capillary tube formation. Blood 97: 652-659, 2001.
17. Kehlen A, Egbert I, Thiele K, Fischer K, Riemann D and Langner J: Increased expression of interleukin-8 and aminopeptidase N by cell-cell contact: Interleukin-8 is resistant to degradation by aminopeptidase N/CD13. Eur Cytokine Netw 12: 316-324, 2001.
18. Ishii K, Usui S, Sugimura Y, Yoshida S, Hioki T, Tatematsu M, Yamamoto H and Hirano K: Aminopeptidase N regulated by zinc in human prostate participates in tumor cell invasion. Int J Cancer 92: 49-54, 2001.
19. Hashida H, Takabayashi A, Kanai M, Adachi M, Kondo K, Kohno N, Yamaoka Y and Miyake M: Aminopeptidase N is involved in cell motility and angiogenesis: Its clinical significance in human colon cancer. Gastroenterology 122: 376-386, 2002.
20. Tokuhara T, Hattori N, Ishida H, Hirai T, Higashiyama M, Kodama K and Miyake M: Clinical significance of aminopeptidase N in non-small cell lung cancer. Clin Cancer Res 12: 3971-3978, 2006.
21. Haraguchi N, Ishii H, Mimori K, Tanaka F, Ohkuma M, Kim HM, Akita H, Takiuchi D, Hatano H, Nagano H, et al: CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest 120: 3326-3339, 2010.
22. Sekine K, Fujii H and Abe F: Induction of apoptosis by bestatin (ubenimex) in human leukemic cell lines. Leukemia 13: 729-734, 1999.
23. Ezawa K, Minato K and Dobashi K: Induction of apoptosis by ubenimex (Bestatin) in human non-small-cell lung cancer cell lines. Biomed Pharmacother 50: 283-289, 1996.
24. Terauchi M, Kajiyama H, Shibata K, Ino K, Nawa A, Mizutani S and Kikkawa F: Inhibition of APN/CD13 leads to suppressed progressive potential in ovarian carcinoma cells. BMC Cancer 7: 140, 2007.
25. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al; SHARP Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008.
26. Lencioni R, Petruzzi P and Crocetti L: Chemoembolization of hepatocellular carcinoma. Semin Intervent Radiol 30: 3-11, 2013.
27. Nagano H, Wada H, Kobayashi S, Marubashi S, Eguchi H, Tanemura M, Tomimaru Y, Osuga K, Umeshita K, Doki Y, et al: Long-term outcome of combined interferon-and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis. Oncology 80: 63-69, 2011.
28. Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
29. Bijnsdorp IV, Giovannetti E and Peters GJ: Analysis of drug interactions. Methods Mol Biol 731: 421-434, 2011.
30. Wickström M, Larsson R, Nygren P, Gullbo J and Aminopeptidase N: Aminopeptidase N (CD13) as a target for cancer chemotherapy. Cancer Sci 102: 501-508, 2011.
31. Hitzerd SM, Verbrugge SE, Ossenkoppele G, Jansen G and Peters GJ: Positioning of aminopeptidase inhibitors in next generation cancer therapy. Amino Acids 46: 793-808, 2014.
32. Naka K, Muraguchi T, Hoshii T and Hirao A: Regulation of reactive oxygen species and genomic stability in hematopoietic stem cells. Antioxid Redox Signal 10: 1883-1894, 2008.
33. Maeda S, Wada H, Naito Y, Nagano H, Simmons S, Kagawa Y, Naito A, Kikuta J, Ishii T, Tomimaru Y, et al: Interferon-acts on the S/G2/M phases to induce apoptosis in the G1 phase of an IFNAR2-expressing hepatocellular carcinoma cell line. J Biol Chem 289: 23786-23795, 2014.
34. Qin LF and Ng IO: Induction of apoptosis by cisplatin and its effect on cell cycle-related proteins and cell cycle changes in hepatoma cells. Cancer Lett 175: 27-38, 2002.
35. Fan C, Zheng W, Fu X, Li X, Wong YS and Chen T: Strategy to enhance the therapeutic effect of doxorubicin in human hepatocellular carcinoma by selenocystine, a synergistic agent that regulates the ROS-mediated signaling. Oncotarget 5: 2853-2863, 2014.
36. Sawafuji K, Miyakawa Y, Weisberg E, Griffin JD, Ikeda Y and Kizaki M: Aminopeptidase inhibitors inhibit proliferation and induce apoptosis of K562 and STI571-resistant K562 cell lines through the MAPK and GSK-3beta pathways. Leuk Lymphoma 44: 1987-1996, 2003.
37. Liang W, Gao B, Xu G, Weng D, Xie M and Qian Y: Possible contribution of aminopeptidase N (APN/CD13) to migration and invasion of human osteosarcoma cell lines. Int J Oncol 45: 2475-2485, 2014.
38. Prasad V, Chandele A, Jagtap JC, Sudheer Kumar P and Shastry P: ROS-triggered caspase 2 activation and feedback amplification loop in beta-carotene-induced apoptosis. Free Radic Biol Med 41: 431-442, 2006.
39. Madesh M, Zong WX, Hawkins BJ, Ramasamy S, Venkatachalam T, Mukhopadhyay P, Doonan PJ, Irrinki KM, Rajesh M, Pacher P, et al: Execution of superoxide-induced cell death by the proapoptotic Bcl-2-related proteins Bid and Bak. Mol Cell Biol 29: 3099-3112, 2009.
40. Balaban RS, Nemoto S and Finkel T: Mitochondria, oxidants, and aging. Cell 120: 483-495, 2005.
41. Chetram MA, Bethea DA, Odero-Marah VA, Don-Salu-Hewage AS, Jones KJ and Hinton CV: ROS-mediated activation of AKT induces apoptosis via pVHL in prostate cancer cells. Mol Cell Biochem 376: 63-71, 2013.
42. McCubrey JA, Lahair MM and Franklin RA: Reactive oxygen species-induced activation of the MAP kinase signaling pathways. Antioxid Redox Signal 8: 1775-1789, 2006.
43. El-Najjar N, Chatila M, Moukadem H, Vuorela H, Ocker M, Gandesiri M, Schneider-Stock R and Gali-Muhtasib H: Reactive oxygen species mediate thymoquinone-induced apoptosis and activate ERK and JNK signaling. Apoptosis 15: 183-195, 2010.
44. Navarro R, Busnadiego I, Ruiz-Larrea MB and Ruiz-Sanz JI: Superoxide anions are involved in doxorubicin-induced ERK activation in hepatocyte cultures. Ann NY Acad Sci 1090: 419-428, 2006.
45. Massaoka MH, Matsuo AL, Figueiredo CR, Farias CF, Girola N, Arruda DC, Scutti JA, Romoff P, Favero OA, Ferreira MJ, et al: Jacaranone induces apoptosis in melanoma cells via ROS-mediated downregulation of Akt and p38 MAPK activation and displays antitumor activity in vivo. PLoS One 7: e38698, 2012.
46. Yu CC, Wu PJ, Hsu JL, Ho YF, Hsu LC, Chang YJ, Chang HS, Chen IS and Guh JH: Ardisianone, a natural benzoquinone, efficiently induces apoptosis in human hormone-refractory prostate cancers through mitochondrial damage stress and survivin downregulation. Prostate 73: 133-145, 2013.
47. Hao W, Yuan X, Yu L, Gao C, Sun X, Wang D and Zheng Q: Licochalcone A-induced human gastric cancer BGC-823 cells apoptosis by regulating ROSmediated MAPKs and PI3K/AKT signaling pathways. Sci Rep 18: 5, 2015.
48. Hartmann KU and Heidelberger C: Studies on fluorinated pyrimidines. XIII. Inhibition of thymidylate synthetase. J Biol Chem 236: 3006-3013, 1961.
49. Wang D and Lippard SJ: Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4: 307-320, 2005.
50. Lenaz L, Necco A, Dasdia T and Di Marco A: Biologic activity of some adriamycin (NSC-123127) derivatives. Cancer Chemother Rep 58: 769-776, 1974.
51. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099-7109, 2004.
52. Hashimoto N, Tsunedomi R, Yoshimura K, Watanabe Y, Hazama S and Oka M: Cancer stem-like sphere cells induced from de-differentiated hepatocellular carcinoma-derived cell lines possess the resistance to anti-cancer drugs. BMC Cancer 14: 722, 2014.
53. Wakita A, Ohtake S, Takada S, Yagasaki F, Komatsu H, Miyazaki Y, Kubo K, Kimura Y, Takeshita A, Adachi Y, et al: Randomized comparison of fixed-schedule versus responseoriented individualized induction therapy and use of ubenimex during and after consolidation therapy for elderly patients with acute myeloid leukemia: The JALSG GML200 Study. Int J Hematol 96: 84-93, 2012.
54. Ichinose Y, Genka K, Koike T, Kato H, Watanabe Y, Mori T, Iioka S, Sakuma A and Ohta M; NK421 Lung Cancer Surgery Group: Randomized double-blind placebo-controlled trial of bestatin in patients with resected stage I squamous-cell lung carcinoma. J Natl Cancer Inst 95: 605-610, 2003.
55. Xu JW, Li CG, Huang XE, Li Y and Huo JG: Ubenimex capsule improves general performance and chemotherapy related toxicity in advanced gastric cancer cases. Asian Pac J Cancer Prev 12: 985-987, 2011.